- Home
- AGEN vs FRD Comparison
AGEN vs FRD Comparison
Compare AGEN & FRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | FRD |
|---|---|---|
| Founded | 1994 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 146.2M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGEN | FRD |
|---|---|---|
| Price | $3.05 | $18.88 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 613.6K | 20.1K |
| Earning Date | 03-10-2026 | 02-09-2026 |
| Dividend Yield | N/A | ★ 0.83% |
| EPS Growth | N/A | ★ 172.86 |
| EPS | N/A | ★ 2.22 |
| Revenue | $106,829,000.00 | ★ $584,350,000.00 |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $68.25 | N/A |
| P/E Ratio | ★ N/A | $8.72 |
| Revenue Growth | N/A | ★ 30.55 |
| 52 Week Low | $1.38 | $12.24 |
| 52 Week High | $7.34 | $24.37 |
Technical Indicators
Market Signals| Indicator | AGEN | FRD |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 41.25 |
| Support Level | $2.76 | $19.38 |
| Resistance Level | $3.15 | $24.37 |
| Average True Range (ATR) | 0.18 | 1.18 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 61.00 | 9.80 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.